Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
4.890
-0.490 (-9.11%)
At close: Sep 15, 2025
-9.11%
Market Cap327.88M
Revenue (ttm)n/a
Net Income (ttm)-63.65M
Shares Out45.87M
EPS (ttm)-1.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume124,229
Average Volume136,560
Open5.380
Previous Close5.380
Day's Range4.770 - 5.380
52-Week Range1.800 - 13.400
Beta0.02
RSI53.15
Earnings DateAug 28, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.